BiotechTube

KRRO-110

Phase 1/2Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alpha-1 Anti-trypsin Deficiency

Conditions

Alpha-1 Anti-trypsin Deficiency, AATD

Trial Timeline

Jan 13, 2025 → Dec 1, 2026

NCT ID
NCT06677307

About KRRO-110

KRRO-110 is a phase 1/2 stage product being developed by Korro Bio for Alpha-1 Anti-trypsin Deficiency. The current trial status is active. This product is registered under clinical trial identifier NCT06677307. Target conditions include Alpha-1 Anti-trypsin Deficiency, AATD.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06677307Phase 1/2Active

Competing Products

13 competing products in Alpha-1 Anti-trypsin Deficiency

See all competitors
ProductCompanyStageHype Score
Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) PlaceboNovartisPhase 2
52
VX-668 + PlaceboVertex PharmaceuticalsPhase 1
32
VX-864Vertex PharmaceuticalsPhase 2
51
ALN-AAT02 + Placebo + ALN-AAT02Alnylam PharmaceuticalsPhase 1/2
38
ARC-AAT Injection + DiphenhydramineArrowhead PharmaceuticalsPhase 1
30
ARC-AAT InjectionArrowhead PharmaceuticalsPhase 2
49
Alpha-1 MPGrifolsPhase 3
74
Alpha-1 MPGrifolsPhase 3
74
WVE-006WaVe Life SciencesPhase 1
28
WVE-006WaVe Life SciencesPhase 1/2
36
INBRX-101/rhAAT-FcInhibrx BiosciencesPhase 1
28
Kamada-AAT for Inhalation, 80mg + Placebo + Kamada-AAT for Inhalation, 160mgKamadaPhase 2
44
Alvelestat (MPH966)Mereo BioPharmaPhase 2
44